Newsroom

News

Every year, the Controlled Release Society (CRS) honors outstanding individuals who have significantly advanced the field of drug delivery. This year, Prof. Claus-Michael Lehr has been awarded the CRS Distinguished Service Award for his long-standing commitment to the society and his influential contributions to pharmaceutical science.

12.06.2025

HIPS

Three intestinal organoids (gray) with spreading Shigella infection (green)

News

Thanks to lab-grown miniature intestines, researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg in collaboration with Uppsala University in Sweden have successfully mapped how aggressive Shigella bacteria infect the human gut. The study, published today in the journal Nature Genetics, opens the door to using cultured human mini-organs to investigate a wide range of other serious infections.

12.06.2025

HIRI

News

New, resistance-breaking drugs are urgently needed to effectively treat infections with antibiotic-resistant germs in the future. Researchers from Saarbrücken and Vienna have now found a possible starting point for the development of such drugs in the natural product Saarvienin A. This novel molecule is capable of killing bacteria even if they are already resistant to clinically used antibiotics. The researchers published their findings in the journal Angewandte Chemie International Edition.

28.05.2025

HIPS

HZI podcast "InFact" with Theresa Graalmann on the topic autoimmune diseases

News

When our immune system chooses the wrong enemy and turns against our own body, autoimmune diseases can result. Dr. Dr. Theresa Graalmann is a physician and clinician scientist who heads the junior research group “Translational Immunology” at TWINCORE – Center for Experimental and Clinical Infection Research. In this episode of the HZI podcast InFact, she explains how rheumatism, lupus, and vascular inflammation develop and how doctors and scientists work together to incorporate patient data and state-of-the-art cell analyses directly into the development of new therapeutic approaches.

27.05.2025

TWINCORE

Study authors Maureen Obara and Dr Matthias Bruhn

News

Monoclonal antibodies against SARS-CoV-2 were considered a promising approach for the prevention and therapy of corona virus infections. However, the ongoing evolution of the virus regularly produces new variants that are no longer neutralized by the antibodies. Researchers from TWINCORE, together with partners from Hanover and Bern, have now been able to clarify the underlying mechanism in more detail. The TWINCORE is a joint institution of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and Hannover Medical School (MHH). Instead of using a single antibody, they propose the combination of several antibodies for treatment. They have published their findings in the scientific journal eBioMedicine.

26.05.2025

TWINCORE

News

Decisions have been made on future Clusters of Excellence in the second round of competition under the Excellence Strategy – the joint initiative of the federal and state governments to further strengthen top-level research at universities in Germany. The Helmholtz Centre for Infection Research (HZI) is part of two of the funded Clusters of Excellence together with university partners: RESIST and NUCLEATE. RESIST at Hannover Medical School (MHH) will receive funding for another seven years. In this cluster, scientists are investigating how people who are susceptible to infection can be better protected. In the newly approved NUCLEATE cluster at the Julius-Maximilians-Universität Würzburg (JMU) with the Technical University of Munich and the Ludwig-Maximilians-Universität München, group leaders from the Helmholtz Institute for RNA-based Infection Research (HIRI), a site of the HZI in cooperation with the JMU, are conducting research into nucleic acid-based therapies. A total of 70 Clusters of Excellence were selected for funding.

26.05.2025

HZI Campus

TWINCORE

CiiM

HIRI

HZI in the media

Das Team des Helmholtz-Instituts für RNA-basierte Infektionsforschung (HIRI) in Würzburg – einem Standort des Braunschweiger ...

12.06.2025

Verband Deutscher Biologen e.V.

University, Uppsala University Hospital, the Helmholtz Institute for RNA-based Infection Research (HIRI) in Germany, Toronto University in

12.06.2025

News Medical

... Körperzellen. Damit tragen wir, wie das Helmholtz-Zentrum für Infektionsforschung ( HZI ) es treffend beschreibt, unseren „ganz ...

11.06.2025

Augsburger Allgemeine

Dr. Katharina Schaufler, PhD Helmholtz-Zentrum für Infektionsforschung Helmholtz-Institut für One Health. Die Abteilung Epidemiologie und ...

10.06.2025

MetropolJournal

Wissenschaftsgeschichte • One Health Surveillance Group des Helmholtz Institute for One Health (HIOH) • Professur für Sozialpsychologie ...

08.06.2025

juraforum.de

Erlangen-Nürnberg (FAU) und des Helmholtz-Instituts für Pharmazeutische Forschung Saarland (HIPS) haben DataSAIL entwickelt – ein ...

06.06.2025

BigData-Insider

Forscher der Saar-Universität und es Helmholtz-Instituts für pharmazeutische Forschung haben in einem internationalen Forschungsprojekt ...

02.06.2025

Die Rheinpfalz

mimic the function of real organs. Researchers at the Helmholtz Center for Infection Research (HZI) in Braunschweig, Germany, led by Dr. Max

01.06.2025

ARCHYDE

Max Kellner und Prof. Josef Penninger – wissenschaftlicher Geschäftsführer des Helmholtz-Zentrums für Infektionsforschung (HZI) – haben ...

01.06.2025

Regional Heute

Register now for the HZI-Newsletter

and stay up to date!

Email address

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.

Please enter here the word as displayed in the picture. This is to prevent spamming.*

If you can't read the word, click here.